Compare Abeona Therapeutics Inc (ABEO) vs VanEck Junior Gold Miners (GDXJ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs VanEck Junior Gold Miners — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while VanEck Junior Gold Miners trades at $95.62. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, VanEck Junior Gold Miners nearer its low. Which is the better fit depends on your goals.
| ABEO | GDXJ | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $7.23 | $156.19 |
52-Week Low | $4.17 | $64.22 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
GDXJ trades at $103.91, up 0.97% today, with technical indicators showing mixed signals (neutral overall, bearish moving averages). The ETF faces headwinds from underperformance versus peers in 2026, with significant portfolio overlap and limited small-cap exposure. Recent news highlights silver price volatility and gold's rally near $4,700, affecting junior miner sentiment.
The outlook remains cautious due to Federal Reserve rate uncertainty and competitive pressures. Investment opportunities hinge on gold price sustainability, but risks include sector underperformance and macroeconomic sensitivity. Analyst sentiment is neutral to bearish, reflecting concerns over the ETF's strategic positioning and recent returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →
